Chronic kidney disease: appropriateness of therapeutic management and associated factors in the AVENIR study.

RATIONALE, AIMS AND OBJECTIVES The nephrology literature contains little information about the global patterns of medication used in the management of patients with chronic kidney disease (CKD). This study aims to evaluate the appropriateness of nephrological therapeutic management of CKD patients compared with current guidelines and to investigate associations between patient characteristics and the quality of therapeutic management. METHODS All adult CKD patients who were starting dialysis in Lorraine (France) between 1 January 2005 and 31 December 2006 and who had been referred to a nephrologist no less than 1 month previously were enrolled. Demographic, clinical, biological and therapeutic data were collected retrospectively from medical records covering the period from the first nephrology consultation to initiation of dialysis. Outcomes of interest were the appropriateness of the therapeutic management of five aspects of CKD: hypertension/proteinuria, anaemia, bone disease, metabolic acidosis and dyslipidemia. Therapeutic care was given a global rating (high, moderate or poor), depending on the number of aspects being managed appropriately. Relationships between the global rating and demographic and clinical characteristics of patients were explored. RESULTS During predialysis nephrology follow-up, 93.1% of the 420 patients enrolled were receiving antihypertensive therapy; 67.1% were taking a renin-angiotensin system inhibitor. Other prescriptions included: erythropoiesis-stimulating agents (67.4%), iron (48.3%), phosphate binders (38.1%), vitamin D (21.1%), bicarbonates (15.5%) and statins (36.2%). Hypertension/proteinuria was managed appropriately in 72.4% of cases, anaemia in 56.2%, bone disease in 16.7%, metabolic acidosis in 60.2% and dyslipidemia in 61.4%. The global quality of care was high in 22.1% of cases, moderate in 65.7% and poor in 12.2%. After adjustment, the more nephrology consultations a patient had before dialysis, the higher the quality of his or her care. CONCLUSION The quality of therapeutic care delivered to CKD patients in nephrology setting was suboptimal when assessed in terms of adherence to guidelines.

[1]  A. Kshirsagar,et al.  Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  Madhumathi Rao,et al.  Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease. , 2005, Kidney international.

[3]  A. Nissenson,et al.  Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. , 2001, Journal of the American Society of Nephrology : JASN.

[4]  John Simes,et al.  Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease , 2004, Circulation.

[5]  F. Port,et al.  Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  H. Feldman,et al.  Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[8]  S. Briançon,et al.  Nephrology referral and appropriateness of therapeutic drug care in chronic kidney disease. , 2006, Journal of nephrology.

[9]  Charles E. McCulloch,et al.  CHRONIC KIDNEY DISEASE AND THE RISKS OF DEATH, CARDIOVASCULAR EVENTS, AND HOSPITALIZATION , 2004 .

[10]  C. Zoccali,et al.  Global approach to cardiovascular risk in chronic kidney disease: reality and opportunities for intervention. , 2006, Kidney international.

[11]  B. Stengel,et al.  Evaluation and Determinants of Underprescription of Erythropoiesis Stimulating Agents in Pre-Dialysis Patients with Anaemia , 2008, Nephron Clinical Practice.

[12]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[13]  C. Leopold,et al.  Time of Erythema Onset after Application of Methyl Nicotinate Ointments as Response Parameter: Influence of Penetration Kinetics and Enhancing Agents , 2006, Skin Pharmacology and Physiology.

[14]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[15]  G J Kuperman,et al.  Blood pressure and angiotensin converting enzyme inhibitor use in hypertensive patients with chronic renal insufficiency. , 2001, American journal of hypertension.

[16]  C. Maxwell,et al.  Measurement, Correlates, and Health Outcomes of Medication Adherence Among Seniors , 2004, The Annals of pharmacotherapy.

[17]  A. Kausz,et al.  Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. , 1999, Journal of the American Society of Nephrology : JASN.

[18]  Michèle Kessler,et al.  Impact of nephrology referral on early and midterm outcomes in ESRD: EPidémiologie de l'Insuffisance REnale chronique terminale en Lorraine (EPIREL): results of a 2-year, prospective, community-based study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  A. Levin,et al.  Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  Jerry Avorn,et al.  The nephrologist's role in the management of calcium-phosphorus metabolism in patients with chronic kidney disease. , 2003, Kidney international.

[21]  A. Kausz,et al.  Management of patients with chronic renal insufficiency in the Northeastern United States. , 2001, Journal of the American Society of Nephrology : JASN.

[22]  F. Locatelli,et al.  Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  Keith C. Norris,et al.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  C. Maingourd,et al.  Démographie des néphrologues en France en 2002. , 2003 .

[25]  K. Sakhaee,et al.  The clinical spectrum of chronic metabolic acidosis: homeostatic mechanisms produce significant morbidity. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  A. Kausz,et al.  Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. , 1999, Journal of the American Society of Nephrology : JASN.

[27]  Bruce Kupelnick,et al.  K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease , 2004 .

[28]  R. Wolfe,et al.  Patterns of medication use in the RRI-CKD study: focus on medications with cardiovascular effects. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  Early referral of Type 2 diabetic patients: are we ready for the assault? , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.